Catalyst Biosciences (DB:HGF2) - Cotización, noticias y análisis

Resumen de acción HGF2

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally.

Acerca de la empresa

HGF2 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Alta volatilidad del precio de la acción en los últimos 3 meses

No tiene una capitalización de mercado significativa (€19M)

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

+ 1 riesgos adicionales

Competidores de Catalyst Biosciences, Inc.

4SC

DB:VSC

€81.5m

Medigene

XTRA:MDG1

€47.2m

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€2.4m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Catalyst Biosciences
Historical stock prices
Current Share Price	US$7.40
52 Week High	US$8.88
52 Week Low	US$2.36
Beta	1.29
1 Month Change	12.13%
3 Month Change	63.12%
1 Year Change	-10.64%
3 Year Change	-89.32%
5 Year Change	-94.67%
Change since IPO	-99.87%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	HGF2	DE Biotechs	Mercado DE
7D	25.8%	-4.9%	-1.5%
1Y	-10.6%	-19.9%	0.9%

Rentabilidad vs. Industria: HGF2 superó al sector German Biotechs , que obtuvo un rendimiento del -23.1% el año pasado.

Rentabilidad vs. Mercado: HGF2 obtuvo unos resultados inferiores a los del mercado German, que fue del 5.9% el año pasado.

Volatilidad de los precios

Is HGF2's price volatile compared to industry and market?
HGF2 volatility
HGF2 Average Weekly Movement	22.1%
Biotechs Industry Average Movement	4.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.0%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: HGF2ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: HGF2(22%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de German.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2002	7	Nassim Usman	www.catalystbiosciences.com

Resumen de fundamentos de Catalyst Biosciences, Inc.

¿Cómo se comparan los beneficios e ingresos de Catalyst Biosciences con su capitalización de mercado?
Estadísticas fundamentales de HGF2
Capitalización bursátil	€18.35m
Beneficios(TTM)	-€41.80m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.4x

Ratio precio-beneficio (PE)

¿Está HGF2 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de HGF2
Ingresos	US$0
Coste de los ingresos	US$1.97m
Beneficio bruto	-US$1.97m
Otros gastos	US$42.27m
Beneficios	-US$44.24m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-17.47
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado HGF2 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción HGF2

Recompensas

Análisis de riesgos

Competidores de Catalyst Biosciences, Inc.

DB:VSC

€81.5m

XTRA:MDG1

€47.2m

XTRA:CNW

€6.5m

XTRA:T5O

€2.4m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. (NasdaqCM:CBIO) in a reverse merger transaction.

Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.

Catalyst Biosciences Announces Update on Letter from Nasdaq Regarding Minimum Bid Price Requirement

Full year 2022 earnings released: US$0.26 loss per share (vs US$2.87 loss in FY 2021)

Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer

Inaugural dividend of US$0.24 per share

Recent updates

Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. (NasdaqCM:CBIO) in a reverse merger transaction.

Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.

Catalyst Biosciences Announces Update on Letter from Nasdaq Regarding Minimum Bid Price Requirement

Full year 2022 earnings released: US$0.26 loss per share (vs US$2.87 loss in FY 2021)

Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer

Inaugural dividend of US$0.24 per share

Insufficient new directors

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)

Catalyst Biosciences Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Insider recently sold €289k worth of stock

Insider recently sold €513k worth of stock

Inaugural dividend of US$1.43 per share

Catalyst Biosciences, Inc. Declares Special One-Time Cash Dividend, Payable on September 20, 2022

Catalyst Biosciences, Inc. Announces Dismissal of Jds1 Litigation

Second quarter 2022 earnings released: EPS: US$1.64 (vs US$0.64 loss in 2Q 2021)

Forecast to breakeven in 2022

JEC II Associates, LLC Reaches an Agreement Catalyst Biosciences

JDS1 LLC Issues an Investor Presentation to Shareholders of Catalyst Biosciences Inc

JDS1, LLC Provides Information to the Shareholders

JEC II Associates Engages in Discussions with Catalyst Biosciences

Insider recently bought €891k worth of stock

JDS1, LLC Provides Information to the Shareholders

Catalyst Biosciences, Inc., Annual General Meeting, Aug 15, 2022

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.79 loss in 1Q 2021)

JDS1 Files a Complaint against Catalyst Biosciences

JDS1 Provides Information to Shareholders of Catalyst Biosciences

Full year 2021 earnings released: US$2.87 loss per share (vs US$2.93 loss in FY 2020)

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian Singer Sends Letter to Catalyst Biosciences

Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency

Third quarter 2021 earnings released: US$0.80 loss per share (vs US$0.73 loss in 3Q 2020)

FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.96 loss in 2Q 2020)

Catalyst Biosciences Announces First Patient Screened for CFI Deficiency in Its CB 4332 Screening and Natural History of Disease Studies

Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from Russell 3000E Value Index

Catalyst Biosciences, Inc. Announces Initiation of Dosing in the Company's Phase 1/2 Study (MAA-202) of Marzeptacog Alfa

Catalyst Biosciences Announces the Dosing of the First Patient in the Crimson 1 Study, the Company's Phase 3 Registration Trial (Maa-304 - Crimson 1)

Revenue beats expectations

New 90-day high: €6.00

Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress

New 90-day high: €5.50

Catalyst Biosciences, Inc. Receives FDA Fast Track Designation for Subcutaneous Marzaa for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors

New 90-day high: €5.40

New 90-day low: €3.70

New 90-day low - €4.18

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Catalyst Biosciences, Inc.

0.0x

-0.4x

Beneficios e Ingresos